<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39008486</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>7</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Inflammatory profiles are associated with long COVID up to 6 months after COVID-19 onset: A prospective cohort study of individuals with mild to critical COVID-19.</ArticleTitle><Pagination><StartPage>e0304990</StartPage><MedlinePgn>e0304990</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0304990</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0304990</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">After initial COVID-19, immune dysregulation may persist and drive post-acute sequelae of COVID-19 (PASC). We described longitudinal trajectories of cytokines in adults up to 6 months following SARS-CoV-2 infection and explored early predictors of PASC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">RECoVERED is a prospective cohort of individuals with laboratory-confirmed SARS-CoV-2 infection between May 2020 and June 2021 in Amsterdam, the Netherlands. Serum was collected at weeks 4, 12 and 24 of follow-up. Monthly symptom questionnaires were completed from month 2 after COVID-19 onset onwards; lung diffusion capacity (DLCO) was tested at 6 months. Cytokine concentrations were analysed by human magnetic Luminex screening assay. We used a linear mixed-effects model to study log-concentrations of cytokines over time, assessing their association with socio-demographic and clinical characteristics that were included in the model as fixed effects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">186/349 (53%) participants had &#x2265;2 serum samples and were included in current analyses. Of these, 101/186 (54%: 45/101[45%] female, median age 55 years [IQR = 45-64]) reported PASC at 12 and 24 weeks after COVID-19 onset. We included 37 reference samples (17/37[46%] female, median age 49 years [IQR = 40-56]). In a multivariate model, PASC was associated with raised CRP and abnormal diffusion capacity with raised IL10, IL17, IL6, IP10 and TNF&#x3b1; at 24 weeks. Early (0-4 week) IL-1&#x3b2; and BMI at COVID-19 onset were predictive of PASC at 24 weeks.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings indicate that immune dysregulation plays an important role in PASC pathogenesis, especially among individuals with reduced pulmonary function. Early IL-1&#x3b2; shows promise as a predictor of PASC.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Wynberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wynberg</LastName><ForeName>Elke</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8245-086X</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Alvin X</ForeName><Initials>AX</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Willigen</LastName><ForeName>Hugo D G</ForeName><Initials>HDG</Initials><Identifier Source="ORCID">0000-0002-4567-3132</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verveen</LastName><ForeName>Anouk</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Pul</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurer</LastName><ForeName>Irma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Leeuwen</LastName><ForeName>Ester M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Aardweg</LastName><ForeName>Joost G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jong</LastName><ForeName>Menno D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieuwkerk</LastName><ForeName>Pythia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2616-1414</Identifier><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prins</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kootstra</LastName><ForeName>Neeltje A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bree</LastName><ForeName>Godelieve J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RECoVERED Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39008486</ArticleId><ArticleId IdType="pmc">PMC11249251</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0304990</ArticleId><ArticleId IdType="pii">PONE-D-23-20788</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>O&#x2019;Mahoney L. L. et al., &#x201c;The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis,&#x201d; EClinicalMedicine, vol. 55, p. 101762, Jan. 2023, doi: 10.1016/j.eclinm.2022.101762</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J. B., Murthy S., Marshall J. C., Relan P., and Diaz J. V., &#x201c;A clinical case definition of post-COVID-19 condition by a Delphi consensus,&#x201d; Lancet Infect. Dis., vol. 22, no. 4, pp. e102&#x2013;e107, Apr. 2022, doi: 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H. E., McCorkell L., Vogel J. M., and Topol E. J., &#x201c;Long COVID: major findings, mechanisms and recommendations,&#x201d; Nat. Rev. Microbiol., vol. 21, no. 3, pp. 133&#x2013;146, Mar. 2023, doi: 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S. et al., &#x201c;Long-COVID in children and adolescents: a systematic review and meta-analyses,&#x201d; Sci. Rep., vol. 12, no. 1, p. 9950, Jun. 2022, doi: 10.1038/s41598-022-13495-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13495-5</ArticleId><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>Attaway A. H., Scheraga R. G., Bhimraj A., Biehl M., and Hatipo&#x11f;lu U., &#x201c;Severe covid-19 pneumonia: pathogenesis and clinical management,&#x201d; BMJ, vol. 372, p. n436, Mar. 2021, doi: 10.1136/bmj.n436</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n436</ArticleId><ArticleId IdType="pubmed">33692022</ArticleId></ArticleIdList></Reference><Reference><Citation>Osuchowski M. F. et al., &#x201c;The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity,&#x201d; Lancet Respir. Med., vol. 9, no. 6, pp. 622&#x2013;642, Jun. 2021, doi: 10.1016/S2213-2600(21)00218-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00218-6</ArticleId><ArticleId IdType="pmc">PMC8102044</ArticleId><ArticleId IdType="pubmed">33965003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M. M. and Haagmans B. L., &#x201c;SARS-CoV-2 pathogenesis,&#x201d; Nat. Rev. Microbiol., vol. 20, no. 5, pp. 270&#x2013;284, May 2022, doi: 10.1038/s41579-022-00713-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Esp&#xed;n E., Yang C., Shannon C. P., Assadian S., He D., and Tebbutt S. J., &#x201c;Cellular and molecular biomarkers of long COVID: a scoping review,&#x201d; EBioMedicine, vol. 91, p. 104552, May 2023, doi: 10.1016/j.ebiom.2023.104552</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104552</ArticleId><ArticleId IdType="pmc">PMC10082390</ArticleId><ArticleId IdType="pubmed">37037165</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M. J. et al., &#x201c;Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection,&#x201d; J. Infect. Dis., vol. 224, no. 11, pp. 1839&#x2013;1848, Dec. 2021, doi: 10.1093/infdis/jiab490</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B. et al., &#x201c;Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations,&#x201d; Cells, vol. 10, no. 2, p. 386, Feb. 2021, doi: 10.3390/cells10020386</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020386</ArticleId><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y. et al., &#x201c;Multiple early factors anticipate post-acute COVID-19 sequelae,&#x201d; Cell, vol. 185, no. 5, pp. 881&#x2013;895.e20, Mar. 2022, doi: 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID Collaborative Group, &#x201c;Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study,&#x201d; Lancet Respir. Med., vol. 10, no. 8, pp. 761&#x2013;775, Aug. 2022, doi: 10.1016/S2213-2600(22)00127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S. W. X. et al., &#x201c;Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients,&#x201d; Open Forum Infect. Dis., vol. 8, no. 6, p. ofab156, Jun. 2021, doi: 10.1093/ofid/ofab156</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab156</ArticleId><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C. et al., &#x201c;Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,&#x201d; Nat. Immunol., vol. 23, no. 2, pp. 210&#x2013;216, Feb. 2022, doi: 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J. et al., &#x201c;Immunologic phenotype of patients with long-COVID syndrome of 1-year duration,&#x201d; Front. Immunol., vol. 13, p. 920627, 2022, doi: 10.3389/fimmu.2022.920627</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.920627</ArticleId><ArticleId IdType="pmc">PMC9451924</ArticleId><ArticleId IdType="pubmed">36090973</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J. et al., &#x201c;Distinguishing features of long COVID identified through immune profiling,&#x201d; Nature, vol. 623, no. 7985, pp. 139&#x2013;148, Nov. 2023, doi: 10.1038/s41586-023-06651-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;Checklists,&#x201d; STROBE. Accessed: Apr. 18, 2024. [Online]. https://www.strobe-statement.org/checklists/</Citation></Reference><Reference><Citation>Wynberg E. et al., &#x201c;Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset,&#x201d; Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 75, no. 1, pp. e482&#x2013;e490, Aug. 2022, doi: 10.1093/cid/ciab759</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab759</ArticleId><ArticleId IdType="pmc">PMC8522402</ArticleId><ArticleId IdType="pubmed">34473245</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gils M. J. et al., &#x201c;Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study,&#x201d; PLoS Med., vol. 19, no. 5, p. e1003991, May 2022, doi: 10.1371/journal.pmed.1003991</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003991</ArticleId><ArticleId IdType="pmc">PMC9113667</ArticleId><ArticleId IdType="pubmed">35580156</ArticleId></ArticleIdList></Reference><Reference><Citation>van Willigen H. D. G. et al., &#x201c;One-fourth of COVID-19 patients have an impaired pulmonary function after 12 months of disease onset,&#x201d; PloS One, vol. 18, no. 9, p. e0290893, 2023, doi: 10.1371/journal.pone.0290893</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0290893</ArticleId><ArticleId IdType="pmc">PMC10495003</ArticleId><ArticleId IdType="pubmed">37695755</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E. D., and Hishmeh L., &#x201c;Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline,&#x201d; BMJ, vol. 372, p. n136, Jan. 2021, doi: 10.1136/bmj.n136</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;Clinical management of COVID-19.&#x201d; Accessed: Apr. 18, 2024. [Online]. https://www.who.int/teams/health-care-readiness/covid-19</Citation></Reference><Reference><Citation>Graham B. L. et al., &#x201c;2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung,&#x201d; Eur. Respir. J., vol. 49, no. 1, p. 1600016, Jan. 2017, doi: 10.1183/13993003.00016-2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00016-2016</ArticleId><ArticleId IdType="pubmed">28049168</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg S. M. et al., &#x201c;From Local Explanations to Global Understanding with Explainable AI for Trees,&#x201d; Nat. Mach. Intell., vol. 2, no. 1, pp. 56&#x2013;67, Jan. 2020, doi: 10.1038/s42256-019-0138-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42256-019-0138-9</ArticleId><ArticleId IdType="pmc">PMC7326367</ArticleId><ArticleId IdType="pubmed">32607472</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabold S. and Perktold J., &#x201c;Statsmodels: Econometric and Statistical Modeling with Python,&#x201d; Jan. 2010, pp. 92&#x2013;96. doi: 10.25080/Majora-92bf1922-011</Citation><ArticleIdList><ArticleId IdType="doi">10.25080/Majora-92bf1922-011</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K. et al., &#x201c;Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2,&#x201d; Nat. Immunol., vol. 25, no. 2, pp. 218&#x2013;225, Feb. 2024, doi: 10.1038/s41590-023-01724-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01724-6</ArticleId><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M. J., Abdel-Mohsen M., Henrich T. J., and Roan N. R., &#x201c;Systems analysis of innate and adaptive immunity in Long COVID,&#x201d; Semin. Immunol., vol. 72, p. 101873, Mar. 2024, doi: 10.1016/j.smim.2024.101873</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2024.101873</ArticleId><ArticleId IdType="pubmed">38460395</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#x3b2; C. et al., &#x201c;The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19,&#x201d; Cell Rep. Med., vol. 3, no. 6, p. 100663, Jun. 2022, doi: 10.1016/j.xcrm.2022.100663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T. et al., &#x201c;Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection,&#x201d; JAMA, vol. 329, no. 22, pp. 1934&#x2013;1946, Jun. 2023, doi: 10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewett S. J., Jackman N. A., and Claycomb R. J., &#x201c;Interleukin-1&#x3b2; in Central Nervous System Injury and Repair,&#x201d; Eur. J. Neurodegener. Dis., vol. 1, no. 2, pp. 195&#x2013;211, Aug. 2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4465544</ArticleId><ArticleId IdType="pubmed">26082912</ArticleId></ArticleIdList></Reference><Reference><Citation>Kihara T., Toriuchi K., Aoki H., Kakita H., Yamada Y., and Aoyama M., &#x201c;Interleukin-1&#x3b2; enhances cell adhesion in human endothelial cells via microRNA-1914-5p suppression,&#x201d; Biochem. Biophys. Rep., vol. 27, p. 101046, Sep. 2021, doi: 10.1016/j.bbrep.2021.101046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrep.2021.101046</ArticleId><ArticleId IdType="pmc">PMC8214032</ArticleId><ArticleId IdType="pubmed">34179516</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendiola A. S. and Cardona A. E., &#x201c;The IL-1&#x3b2; phenomena in neuroinflammatory diseases,&#x201d; J. Neural Transm. Vienna Austria 1996, vol. 125, no. 5, pp. 781&#x2013;795, May 2018, doi: 10.1007/s00702-017-1732-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1732-9</ArticleId><ArticleId IdType="pmc">PMC5699978</ArticleId><ArticleId IdType="pubmed">28534174</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanou M.-I. et al., &#x201c;Neurological manifestations of long-COVID syndrome: a narrative review,&#x201d; Ther. Adv. Chronic Dis., vol. 13, p. 20406223221076890, 2022, doi: 10.1177/20406223221076890</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221076890</ArticleId><ArticleId IdType="pmc">PMC8859684</ArticleId><ArticleId IdType="pubmed">35198136</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Rial J. et al., &#x201c;Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology,&#x201d; Front. Immunol., vol. 11, p. 560381, 2020, doi: 10.3389/fimmu.2020.560381</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.560381</ArticleId><ArticleId IdType="pmc">PMC7538662</ArticleId><ArticleId IdType="pubmed">33072099</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B., Julg B., Mohandas S., and Bradfute S. B., &#x201c;Viral persistence, reactivation, and mechanisms of long COVID,&#x201d; eLife, vol. 12, p. e86015, doi: 10.7554/eLife.86015</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86015</ArticleId><ArticleId IdType="pmc">PMC10159620</ArticleId><ArticleId IdType="pubmed">37140960</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke R. W. and Lumeng C. N., &#x201c;Pathways to Severe COVID-19 for People with Obesity,&#x201d; Obes. Silver Spring Md, vol. 29, no. 4, pp. 645&#x2013;653, Apr. 2021, doi: 10.1002/oby.23099</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.23099</ArticleId><ArticleId IdType="pmc">PMC7753541</ArticleId><ArticleId IdType="pubmed">33270351</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>